JENEX CLOSES $977,000 FINANCING

FOR IMMEDIATE RELEASE

March 23, 2004

Burlington, Ontario

Burlington, Ontario - THE JENEX CORPORATION ("Jenex" or the "Corporation") (TSX Venture Exchange – “JEN”), announces that it has successfully completed a $977,647 non-brokered financing.  The financing consisted of five million units at 18 cent per unit and 304,498 units at 25.5 cents per unit. Each unit consists of one common share and one common share purchase warrant. Each full warrant entitles the holder to purchase one additional common share of the corporation at a purchase price of  40  cents  per common share, on or before that day which is the earlier of; (i) March 22, 2005; or (ii) any 10-day period immediately  following  a period  where  the  corporation's  common  shares have traded at a weighted daily average price greater than or equal to 80 cents  for  10  consecutive trading  days  and  the  average  daily trading volume exceeds 5,000 common shares per day. The common shares and warrants are subject to a hold period expiring on July 22, 2004.

The proceeds from the financing will be used to prepare for the Canadian launch in late 2004 of the corporation's cold sore prevention product. In addition,  the  corporation  announces  the  TSX  Venture  Exchange  has accepted the corporation's proposed shares-for-debt transaction reported in Stockwatch news on March 1, 2004, regarding the issuance of  623,473  units at  a deemed issue price of 24 cents per unit to settle outstanding debt of $149,634 with various arm's-length creditors of the corporation. Each  unit consists  of a common shares and purchase warrant which is exercisable into a common share of the corporation at an exercise  price  of  40  cents  per common  share  for  a  one-year  period. The common shares and warrants are subject to a hold period expiring on July 22, 2004.